Comments on "Well-Differentiated Thyroid Carcinoma with Concomitant Hashimoto’s Thyroiditis Present with Less Aggressive Clinical Stage and Low Recurrence"

Cunha, Lucas Leite; Ward, Laura Sterian

doi:10.1007/s12022-011-9171-x

Cited by 10 publications

(4 citation statements)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our cohort, the presence of concurrent CLT was also significantly correlated with favorable prognostic features including female gender, no extrathyroidal tumor invasion, absence of metastasis at diagnosis, and small tumors, thus confirming the tight relationship between concurrent autoimmunity and histopathological features of low aggressiveness [ 99 ]. Using the same criteria introduced by Huang et al to define recurrence, metastasis, and disease-free survival, a log-rank test also confirmed that the absence of CLT was more frequent in our patients who had recurrences, suggesting that autoimmune activity against the gland may exert a protective effect on the outcome of DTC patients [ 100 ].…”

Section: Relationship Between Chronic Lymphocytic Inflammation Andsupporting

confidence: 68%

Immune Response in Thyroid Cancer: Widening the Boundaries

Ward

2014

Scientifica

Self Cite

View full text Add to dashboard Cite

The association between thyroid cancer and thyroid inflammation has been repeatedly reported and highly debated in the literature. In fact, both molecular and epidemiological data suggest that these diseases are closely related and this association reinforces that the immune system is important for thyroid cancer progression. Innate immunity is the first line of defensive response. Unlike innate immune responses, adaptive responses are highly specific to the particular antigen that induced them. Both branches of the immune system may interact in antitumor immune response. Major effector cells of the immune system that directly target thyroid cancer cells include dendritic cells, macrophages, polymorphonuclear leukocytes, mast cells, and lymphocytes. A mixture of immune cells may infiltrate thyroid cancer microenvironment and the balance of protumor and antitumor activity of these cells may be associated with prognosis. Herein, we describe some evidences that immune response may be important for thyroid cancer progression and may help us identify more aggressive tumors, sparing the vast majority of patients from costly unnecessary invasive procedures. The future trend in thyroid cancer is an individualized therapy.

show abstract

Section: Relationship Between Chronic Lymphocytic Inflammation Andsupporting

confidence: 68%

Immune Response in Thyroid Cancer: Widening the Boundaries

Ward

2014

Scientifica

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to numerous reports, metastatic foci in cervical lymph nodes accompany both “clear” cancer forms and tumors presenting with symptoms of chronic lymphocytic thyroiditis. The degree of nodal involvement—differently reported in various publications—ranged from 7 to 49 % [34–36]. In one of the recent articles, Paulson et al [37] suggest that a lower number of nodal metastases to the central compartment are a result of a coexisting autoimmune disease and the protective role it plays in neoplastic spreads beyond the primary focus area.…”

Section: Discussionmentioning

confidence: 99%

Coexistence of papillary thyroid cancer with Hashimoto thyroiditis

Konturek

Barczyński

Wierzchowski

et al. 2012

Langenbecks Arch Surg

101

View full text Add to dashboard Cite

AimsConflicting data have been reported with regard to Hashimoto thyroiditis (HT) and risk of malignancy. The aim of this study was to evaluate coexistence of papillary thyroid cancer (PTC) with HT.Patients and methodsThis is a retrospective cohort study in which HT was diagnosed in 452 (F/M ratio = 405:47, median age 53.5 ± 12.1 years) of 7,545 patients qualified for thyroidectomy throughout the years 2002 to 2010. Pathological reports were reviewed to identify prevalence of PTC in HT vs. non-HT patients.ResultsPTC was diagnosed in 106 of 452 (23.5 %) HT patients vs. 530 of 7,093 (7.5 %) non-HT patients (p < 0.001). Metastases to level VI lymph nodes were observed in 81 of 106 (76.4 %) patients with PTC in HT vs. 121 of 530 (22.8 %) patients with PTC in non-HT disease (p < 0.001).ConclusionsHT was associated with a threefold increase of PTC prevalence as compared to other non-HT thyroid diseases, and the spread of PTC to level VI lymph nodes was four times more frequent in HT than in non-HT patients.

show abstract

“…These data support the hypothesis that immune responses may influence DTC progression . Previous studies also suggested that the presence of a local inflammatory response and concurrent CLT may predict a more favourable prognosis for patients with DTC. However, the actual impact of the immune system, the presence of autoimmune thyroid diseases and their relationship with cancer development and progression remain controversial …”

Section: Introductionmentioning

confidence: 99%